Respiratory syncytial virus clinical trial


If you are between 18 and 49 years of age and are 24 to 33 weeks pregnant.

Trial status:


Respiratory syncytial virus, or RSV, is a common respiratory (lungs and airways) virus that usually causes mild, cold-like symptoms. Often people recover in a week or two, but RSV can be deadly, especially for infants and older adults.

Currently, there is no specific treatment or approved vaccine to protect our infant population against RSV. Mater is running a RSV vaccine study in pregnant women at Mater Mothers' Hospital and we need your help.

If you are between 18 and 49 years of age and are 24 to 33 weeks pregnant and are interested in being part of this important study, please contact our team for more information.

All research clinical trials news

Mater Research is calling for 50 adults in south-east Queensland to join the global clinical trial of a potential new protein-based COVID-19 vaccine, the latest vaccine trial being run at Mater...



Volunteers needed for new COVID-19 vaccine trial

World Clinical Trials Day seeks to recognise the doctors, nurses and scientists who conduct clinical trials and thank them for the significant impact they have on improving public health for...



How clinical trials inform new treatment options for patients

During a world first therapy conducted at the Princess Alexandra Hospital by Mater Researcher and Haematologist Professor Maher Gandhi a 46-year-old patient Scott Griffiths has been successfully...



Mater Researcher uses breakthrough therapy to cure lymphoma patient

Displaying results 1-3 (of 6)
 |<  < 1 - 2  >  >|